WEREWOLF THERAPEUTICS, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2021-08-12
- WEREWOLF THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2021-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2020-06-30 was 59.00K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month |
|---|---|---|
| 2021-06-30 | 0.00 shares 10-Q · filed 2021-08-12 | 0.00 shares 10-Q · filed 2021-08-12 |
| 2020-06-30 | 59.00K shares 10-Q · filed 2021-08-12 | 0.00 shares 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |